Company News Summary
Phosphagenics Completes Pre-Clinical Study of Oxycodone/TPM Technology
Original announcement: Phosphagenics Further Expands Pain Portfolio
Phosphagenics has completed a pre-clinical study demonstrating that its oxycodone/TPM technology can reduce local pain without the need to deliver oxycodone into the bloodstream. The Company intends to commence clinical trials in Quarter 3 of 2013.
See more ASX300 News Announcements